RxDoctor Payments Data

Mitesh Lotia, MD

Neurology · Winter Park, FLNPI 1871759175

Payments from drug & device makers

$326,939in general payments, 2019–2025

Across 168 payments — averaging $1946.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$210K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$56K
  • Abbott$46K
  • Orphalan Inc$6K
  • Neurocrine Biosciences, Inc.$5K
  • AstraZeneca$3K
  • plus $1K from 7 others

What the payments were for

  • Consulting fees$7,69314%
  • Speaking & faculty fees$32,53358%
  • Travel & lodging$11,21920%
  • Food & beverage$4,2828%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.12$210,442
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)33$55,771
Abbott100$45,577
Orphalan Inc8$5,740
Neurocrine Biosciences, Inc.1$5,000
AstraZeneca1$2,950
AbbVie4$900
Insightec,inc3$395
Medtronic1$48
GE HealthCare2$37
Microtransponder, Inc.1$36
Amgen1$24
Kyowa Kirin, Inc.1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$326,939 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$188,758
Medicare patients
299
Services billed
15,497

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa55$75,901
NuplazidPimavanserin Tartrate13$55,828
BotoxOnabotulinumtoxina45$53,534
GocovriAmantadine Hcl15$38,986
Carbidopa-LevodopaCarbidopa/Levodopa633$18,939
RexultiBrexpiprazole12$17,278
AmantadineAmantadine Hcl92$8,578
Carbidopa19$5,195
Propranolol Hcl ErPropranolol Hcl72$3,744
RivastigmineRivastigmine Tartrate60$3,492
Entacapone22$3,395
Propranolol Hcl116$2,263
Gabapentin128$2,239
Carbidopa-Levodopa ErCarbidopa/Levodopa73$1,923
Ropinirole Hcl69$1,847

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox$900$53,53445 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.

Other neurology in Winter Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →